IPD Analytics

Meet us in New York City on March 17–20, 2025, for DCAT Week, hosted by the Drug, Chemical & Associated Technologies Association (DCAT). Be sure to set up a meeting with Melissa Beigel or Tim Powers to learn more about the newest features within the IPD Platform.

IPD’s latest DATA STACK Trend Report shows that, among single-source brand drugs that had price increases in January 2025, most had increases of 2%-4%. This marks a shift downward from the 4%–6% range observed in 2023 and 2024. Additionally, over 83% of price increases in January 2025 remained at or below 6%, reflecting a trend of stabilization compared to previous years. Read the report to find out more: https://lnkd.in/e7hzmvTZ

Bethany Holderread, PharmD, Associate Director of Clinical Pharmacy at IPD Analytics, will be speaking about novel therapies approved by the FDA in the past year on Friday, February 21, at 8:25 AM at the ADURS Symposium. Learn more: https://adurs.com/ #clinicaldevelopment #drugdevelopment #healthcare #FDA #pharmaceuticals

We are pleased to have IPD Analytics as our Networking partner for the 14th Annual Pharma IPR India Conference from March 4th-6th, 2025 at The Westin Mumbai Garden City, Goregaon. IPD Analytics is the trusted partner for 750+ organizations worldwide, including Intellectual Property, Business Development, and Portfolio teams in Generic and Brand Pharma. More info at: https://lnkd.in/eaE7qqRp Grow your presence in the evolving pharmaceutical industry with us. Explore in-depth details at www.pharmaipr-india.com or reach out to [email protected] for more information. Ruchi Kedia Rima Fodkar Visha Murthy Archana Shantharam Aishwarya Upadhyay Saleem Pasha Pratibha Gupta #PharmaIPRIndia #CPHIConferences #InformaMarkets

The Southwest AMCP Affiliate welcomes Bethany Holderread, PharmD, new Associate Director at IPD Analytics to discuss Pipeline and New Drug Update at our Day of Education at University of Houston on Saturday, February 1st! ??Register today: https://lnkd.in/gcYx6WGM For more information regarding the Day of Education, please visit the registration website.

IPD Analytics has released its 2025 Hospital Inpatient Pipeline Therapies Report. The report focuses on potential approvals and launches with near-term impact on hospitals and health-systems. https://lnkd.in/e7hzmvTZ ? The report offers hospital pharmacy leaders visibility into potential FDA approvals for budget planning purposes for the current fiscal year. With increasing numbers of FDA approvals of high-cost complex therapies, including gene therapies and other therapies that may require inpatient hospitalization for administration and/or monitoring, a focus on hospital inpatient pipeline therapies helps tailor health-system budgets and formulary management strategies. Such planning involves assessment of the potential adoption of these new therapies, if approved, and resulting increases in the costs of care. #bentracimab #BTGInternational #SERBPharmaceuticals #SFJPharmaceuticals #Revascor #Mesoblast #Lumitrace #MediBeacon #treosulfan #MedexusPharmaceuticals #suzetrigine #Vertex

IPD Analytics has released its?Drug Pipeline and Trend Impact Report: 1H 2025, a publication that highlights late-stage pipeline drugs with the potential to significantly affect the competitive landscape and payer drug spend across trending drug classes. For each of the 41 drugs identified as having potentially high impact, the report provides an assessment of clinical efficacy and safety, expected place in therapy, approval outlook, estimated cost, and information regarding the reimbursement and distribution channel. Read it now: https://lnkd.in/e7hzmvTZ #drugpipeline #drugpricing #Amvuttra #Alynylam #semaglutide #NovoNordisk #Suzetrigine #Vertex #Brensocatib #Insmed #Depemokimab #GSK

Join Jeffrey Casberg, RPh, MS, our Senior Vice President of Clinical Pharmacy, on Thursday, January 9, 2025, at 12:00 PM, for Managed Healthcare Executive’s webinar presentation, “Your Guide to 2025: Pharma, Formularies, the Pipeline, and More.” In this webinar, the speakers will discuss drugs that will enter the market this year; formulary placement and pricing strategies; managing the cost of GLP-1s and weight loss; pharmacy benefit manager (PBM) reform; and the 340B program. Be sure to listen in: https://lnkd.in/gtUb9Hmh #drugpricing #drugpipeline #healthcare #managedcare?

IPD has just released a new report, “IPD’s 2025 Preview: 10 Pharmacy and Healthcare Trends to Anticipate.” In this report, IPD’s Executive Clinical Pharmacy Team delves into notable drug approvals, advancements in treatment of rare diseases, oncology breakthroughs, GLP-1 RA affordability and access, impacts expected from AI, and more. Read it now: https://lnkd.in/e7hzmvTZ #healthcare #pharmacy #drugpricing #clinicaldevelopment #GLP1 #oncology #ai #raredisease #drugapprovals

IPD Analytics has released its Biosimilar Pipeline Report for 1H 2025, which provides an outlook for potential approvals and launches across the biosimilar landscape over the 2025–2028 horizon. In addition, the report examines trends in average sales prices (ASPs) of reference medical-benefit products and provides the full list of biosimilars approved in 2024 to date. Read the report now: https://lnkd.in/e7hzmvTZ Subscribers of IPD can use this report as a companion to our online Clinical Development Tracker within our?Payer & Provider Insights?platform, which provides up-to-date clinical pipeline information on thousands of products across various disease classes and therapeutic areas. #biosimilars #clinicaldevelopment #drugpricing #stelara #janssen #xolair #novartis #prolia #amgen #ocrevus #genentech #eylea #regeneron